Cationic Lipid Microbubble Nucleic Acid Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current ultrasound/microbubble targeted delivery (UMTD) systems for gene therapy are limited by inefficient DNA binding, unclear mechanisms of action, and low efficiency in delivering genes to tumors, requiring direct injection of microbubbles into tumors and facing challenges with DNA stability and transduction efficiency.
Innovation Solution
Development of custom-designed microbubbles with positively charged lipid shells that stably bind nucleic acids, including siRNA and DNA vectors, and use of ultrasound to target and burst microbubbles within tumors, enhancing gene delivery and expression by improving DNA binding and stability, and enabling non-invasive, systemic delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If microbubbles are used for gene therapy delivery, then non-viral delivery safety and flexibility are improved, but DNA binding efficiency and stability are insufficient
Solution Approach 1:
The patent modifies the microbubble shell composition by incorporating positively charged lipids (such as distearoylphosphatidyl-ethanolamine or cholesterol derivatives with cationic groups) to change the surface charge parameter from neutral/negative to positive, enabling electrostatic binding with negatively charged DNA phosphate backbones. This parameter change directly addresses the DNA binding efficiency problem while maintaining the non-viral safety profile.
Solution Approach 2:
The patent creates composite microbubble structures by combining lipid shell materials with cationic DNA-binding agents (such as polyethylenimine or cationic lipids) to form a hybrid delivery vehicle. This composite approach allows the microbubble to simultaneously provide non-viral safety, stable DNA binding, and protected nucleic acid delivery, resolving the contradiction between safety and binding efficiency.
2Manufacturing precision
If microbubbles are injected directly into tumors, then gene delivery to tumors is achieved, but invasive procedure complexity increases
Solution Approach 1:
The patent introduces an ultrasound field as an intermediary energy source to trigger microbubble destruction and gene release at the tumor site. Instead of requiring direct invasive injection, systemically administered microbubbles are activated by external ultrasound, which acts as a non-invasive mediator to achieve localized tumor transfection. This eliminates the need for invasive tumor injections while maintaining delivery efficiency.
Solution Approach 2:
The patent replaces the mechanical injection system (needles, syringes, direct tumor puncture) with an acoustic field-based activation system. Ultrasound waves provide the mechanical energy needed for microbubble cavitation and membrane disruption without requiring physical penetration of the tumor, substituting a non-invasive acoustic mechanism for the invasive mechanical injection approach.
3Productivity
If ultrasound parameters are optimized for microbubble destruction, then gene transduction efficiency is improved, but DNA stability during delivery is compromised
Solution Approach 1:
The patent performs preliminary protection of DNA by coating it with cationic lipids or polymers before microbubble association, creating a stable complex that shields DNA from degradation during circulation. This preliminary stabilization action ensures DNA survives the delivery journey intact, while subsequent ultrasound-triggered microbubble destruction releases the protected DNA for efficient cellular transduction, resolving the stability-efficiency contradiction.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The custom microbubble system achieves efficient and stable delivery of therapeutic genes to tumors, slowing tumor growth by creating transgenic cells that express therapeutic genes, such as the HSV-TK gene, and allows for repeated treatments with improved safety and specificity.
Implementation Method 1
custom-designed microbubbles with positively charged lipid shells that stably bind nucleic acids
Implementation Method 2
use of ultrasound to target and burst microbubbles within tumors
Data Source
AI summary
The invention pertains to a lipid-based microbubble stably binding a plurality of nucleic acids, and a method of delivering the microbubble and nucleic acids to a specific target site using ultrasound. The delivered nucleic acids create transgenic cells (i.e., for example, a transgenic tumor cell), wherein the transgenic cell expresses the proteins encoded by the delivered nucleic acids. This technology provides a significant improvement for microbubble-drug delivery platforms as known microbubble do not efficiently bind nucleic acids. The improvements described herein include but are not limited to identifying proper lipid proportionality ratios and/or cationic surfactant layers that provide an optimum mechanical index compatible with ultrasonics. Microbubble perfusion and/or nucleic acid delivery may be performed by a combination of imaging and ultrasound/microbubble targeted delivery to simultaneously perform low power two-dimensional imaging and high power microbubble destruction. Such systems are useful in therapeutics and/or diagnostics. For example, the data disclosed herein shows proof of principle in conjunction with the delivery of therapeutic siRNA molecules to slow tumor growth.